History | Age-related macular degeneration | Guidance | NICE

Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
View all What we do
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

History

Guidance published

Consultation comments and responses (PDF 3.98 MB)

Published:

23 January 2018
Committee member list (PDF 384 KB)

Published:

23 January 2018

Stakeholder list updated

Stakeholder list (PDF 194 KB)

Published:

22 January 2018

Equality and health inequalities assessment

Equality impact assessment 3 (PDF 143 KB)

Published:

09 October 2017
Equality impact assessment 4 (PDF 186 KB)

Published:

22 January 2018
Equality impact assessment 5 (PDF 207 KB)

Published:

23 January 2018

Draft guidance consultation

Draft guidance consultation
Draft guideline (PDF 4.4 MB)

Published:

13 July 2017
Guideline appendix D (PDF 748 KB)

Published:

13 July 2017
Guideline appendix C (PDF 1.06 MB)

Published:

13 July 2017
Guideline appendix B (PDF 395 KB)

Published:

13 July 2017
Guideline appendix A (PDF 364 KB)

Published:

13 July 2017
Guideline appendix N (PDF 1.01 MB)

Published:

13 July 2017
Guideline appendix M (PDF 1.18 MB)

Published:

13 July 2017
Guideline appendix L (PDF 571 KB)

Published:

13 July 2017
Guideline appendix K (PDF 342 KB)

Published:

13 July 2017
Guideline appendix I (PDF 384 KB)

Published:

13 July 2017
Guideline appendix H (PDF 7.33 MB)

Published:

13 July 2017
Guideline appendix G (PDF 7.68 MB)

Published:

13 July 2017
Guideline appendix F (PDF 2.25 MB)

Published:

13 July 2017
Guideline appendix E (PDF 16.16 MB)

Published:

13 July 2017
Short version of draft guideline LARGE FONT (PDF 477 KB)

Published:

13 July 2017
Short version of draft guideline (PDF 473 KB)

Published:

13 July 2017
Comments form LARGE FONT (MSWord 63 KB)

Published:

13 July 2017
Comments form (MSWord 63 KB)

Published:

13 July 2017
Guideline appendix J (PDF 8.86 MB)

Published:

13 July 2017

Committee list updated

Committee member list (PDF 363 KB)

Published:

03 March 2017

Pre-consultation documents released

Search strategies (PDF 745 KB)

Published:

02 March 2017
Review questions (PDF 239 KB)

Published:

02 March 2017
Economic plan (PDF 152 KB)

Published:

02 March 2017

Committee meetings

Committee meeting
Minutes 1 (PDF 258 KB)

Published:

26 February 2016
Minutes 2 (PDF 257 KB)

Published:

26 February 2016
Minutes 3 (PDF 298 KB)

Published:

26 February 2016
Minutes 5 (PDF 243 KB)

Published:

06 April 2016
Minutes 4 (PDF 238 KB)

Published:

06 April 2016
Minutes 6 (PDF 265 KB)

Published:

24 May 2016
Minutes 6 (PDF 296 KB)

Published:

25 May 2016
Committee meeting: 7
Minutes 7 (PDF 416 KB)

Published:

07 December 2016
Committee meeting: 8
Minutes 8 (PDF 371 KB)

Published:

07 December 2016
Committee meeting: 9
Minutes 9 (PDF 504 KB)

Published:

07 December 2016
Committee meeting: 10
Minutes 10 (PDF 525 KB)

Published:

07 December 2016
Committee meeting: 11
Minutes (PDF 561 KB)

Published:

10 January 2017
Committee meeting: 12
Minutes 12 (PDF 406 KB)

Published:

05 January 2017
Committee meeting: 13
Minutes 13 (PDF 375 KB)

Published:

13 February 2017
Committee meeting: 14
Minutes 14 (PDF 374 KB)

Published:

06 September 2017
Committee meeting: 15
Minutes 15 (PDF 358 KB)

Published:

18 September 2017

Scope published

Final scope (PDF 240 KB)

Published:

27 October 2015

Draft scope consultation

Draft scope consultation
Draft scope (PDF 231 KB)

Published:

27 October 2015
Consultation comments and responses (PDF 678 KB)

Published:

27 October 2015
Equality impact assessment Section 1 (PDF 122 KB)

Published:

20 April 2016
Equality impact assessment Section 2 (PDF 136 KB)

Published:

20 April 2016

Macular degeneration: the guideline committee

Macular degeneration: committee membership (PDF 14 KB)

Published:

26 August 2015

Macular degeneration: stakeholder workshop notes

Macular degeneration: stakeholder workshop notes (PDF 198 KB)

Published:

08 May 2015

Macular degeneration: remit

Macular degeneration: remit (PDF 10 KB)

Published:

04 December 2012